[International] [Peer Reviewed] 

About OAMJMS

Our policies

OAMJMS Online

For contributors

Services

Why publish in OAMJMS?
Editors
Boards
Publication fee
Indexing
Membership
Evaluation

Editorial & publishing policies
Competing interests policy 
Open access
Open access license

Reviewer guidelines
CrossCheck Plagiarism Screening
CrossMark Policy Page

Online first
Current issue
Journal archive

Online first fact sheet
Free Registration
Contact
Webmail

Guidelines  [pdf]
Online submission MC
Online submission OJS
Help for authors
Cover letter
Reviewers of OAMJMS

Reviewer Summary

Transliteration
Subscriptions

Sponsors
Reprints and permissions
Resources
ICMJE Disclosure Form

 

Open Access Macedonian Journal of Medical Sciences.

http://dx.doi.org/10.3889/oamjms.2015.053

Clinical Science

 

 

The Effect of Combined Therapy ICS/LABA and ICS/LABA plus Montelukast in Patients with Uncontrolled Severe Persistent Asthma Based on the Serum IL-13 and FEV1


 

Elena Jovanovska Janeva1, Zlatica Goseva1, Angjelko Gjorchev1, Angela Debreslioska1, Mirko Spiroski2, Beti Zafirova3, Magdalena Genadieva Dimitrova4

1University Clinic of Pulmonology and Allergology, Faculty of Medicine, Ss Cyril and Methodius University of Skopje, Skopje, Republic of Macedonia; 2Institute of Immunobiology and Human Genetics, Faculty of Medicine, Ss Cyril and Methodius University of Skopje, Skopje, Republic of Macedonia; 3Institute of Epidemiology and Biostatistics, Faculty of Medicine, Ss Cyril and Methodius University of Skopje, Skopje, Republic of Macedonia; 4University Clinic of Gastroenterohepatology, Faculty of Medicine, Ss Cyril and Methodius University of Skopje, Skopje, Republic of Macedonia

 

Abstract

 

 

BACKGROUND: IL-13 is one of many cytokines responsible for the chronic inflammation of asthma.

AIM: The aim of this study was to determine the effect of combined therapy ICS/LABA and ICS/LABA plus Montelukast in patients with uncontrolled severe persistent asthma by analyzing of serum IL-13 and FEV1 before the treatment and after 6 months of therapy.

MATERIAL AND METHODS: In study we included two groups. First group with 27 patients were treated with ICS/LABA. Second group with 29 patients were treated with ICS/LABA plus Montelukast. In each of them were measured serum IL-13 levels by the ELISA method and FEV1 before and after 6 months of treatment. Results were statistically analyzed according to the Wilcoxon Pairs Test and T-test.

RESULTS: The obtained results in both groups showed that the serum IL-13 before the start of therapy were much higher and after 6 months of treatment significantly reduces their value, which in the second group were more expressed. The difference in the average value of FEV1 in both groups before and after therapy was statistically significant.

CONCLUSION: Treatment with ICS/LABA plus Montelukast proved superior compared to therapy of ICS/LABA in patients with uncontrolled severe persistent asthma and allows achievement of well controlled of asthma with subjective clinical improvement.

..................

Citation: Jovanovska Janeva E, Goseva Z, Gjorchev A, Debreslioska A, Spiroski M, Zafirova B, Genadieva Dimitrova M. The Effect of Combined Therapy ICS/LABA and ICS/LABA plus Montelukast in Patients with Uncontrolled Severe Persistent Asthma Based on the Serum IL-13 and FEV1. OA Maced J Med Sci. http://dx.doi.org/10.3889/oamjms.2015.053
Key words: asthma; IL-13; FEV1; ICS/LABA; Montelukast.
*Correspondence: Elena Jovanovska Janeva, MD, MSc. University Clinic of Pulmonology and Allergology, Faculty of Medicine, Ss Cyril and Methodius University of Skopje, Skopje, Republic of Macedonia. E-mail: eli.janeva@yahoo.com
Received: 29-Mar-2015; Revised: 28-Apr-2015; Accepted: 29-Apr-2015; Online first: 07-May-2015
Copyright: © 2015 Elena Jovanovska Janeva, Zlatica Goseva, Angjelko Gjorchev, Angela Debreslioska, Mirko Spiroski, Beti Zafirova, Magdalena Genadieva Dimitrova. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Competing Interests: The authors have declared that no competing interests exist.
 

 

< Previous | Next Article >

Table of contents

 

This Article (free)

Full text (pdf)

Full text OnlineFirst (pdf)


Google Scholar

- Jovanovska Janeva E
- Goseva Z
- Gjorchev A
- Debreslioska A
- Spiroski M
- Zafirova B
- Genadieva Dimitrova M


PubMed

- Jovanovska Janeva E
- Goseva Z
- Gjorchev A
- Debreslioska A
- Spiroski M
- Zafirova B
- Genadieva Dimitrova M

 

Altmetric
 

 


Publisher: ID Design 2012/DOOEL Skopje, Republic of Macedonia.

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics.

OAMJMS is an international peer-reviewed, Open Access journal published four times per year. OAMJMS Online (eISSN 1857-9655) offers free access to all articles.


Creative Commons Attribution LicenseAll site content, except where otherwise noted, is licensed under a Creative Commons Attribution License.